Evvy Raises $40 Million as Vaginal Microbiome Push Expands to Fertility
Evvy raises a $40 million Series B to expand its vaginal microbiome platform, fertility research, AI guidance and personalized care for patients across the US.
Summary
Evvy announced a $40 million Series B led by Catalio Capital Management on Tuesday, September 15, 2026. Priyanka Jain, Laine Bruzek and Pita Navarro founded the company in 2021. Evvy describes its product as the only at-home, CLIA-certified and CLEP-certified mNGS test analyzing vaginal microbes from one swab. Its laboratory sequences mailed samples, platform clinicians review them, and patients receive portal results with a diagnosis, clinical interpretation, next steps and relevant prescription care. Evvy says it serves more than 100,000 US patients and works with 3,000 practitioners. Its data has supported 15 peer-reviewed publications and abstracts, novel bacterial vaginosis subtypes and hundreds of previously uncatalogued vaginal microbiome genomes.
EvvyAI, introduced in May, converts microbiome data into real-time guidance while directing questions requiring expert judgment to clinicians. Evvy aims to connect microbiome biology, symptoms, interventions and outcomes, addressing limited representative female biological data and women’s health gaps in leading AI models. Its first major expansion beyond vaginal health targets fertility, with research linking microbiomes to infertility, gynecological cancer, preterm birth, IVF success and recurrent pregnancy loss, following a prospective IVF-clinic study launched in 2025. Jain ultimately envisions a data-rich, noninvasive, at-home alternative to the Pap smear covering infections, inflammation, fertility, PCOC, endometriosis, premenopause and HPV progression. Juno Bio, Tiny Health and Daye also operate in vaginal health.
Positives
- $40 million from a Series B led by Catalio Capital Management gives Evvy fresh capital as it expands into fertility research.
- More than 100,000 US patients and 3,000 practitioners now use or support Evvy’s vaginal microbiome platform.
- 15 peer-reviewed publications and abstracts have emerged alongside novel bacterial vaginosis subtypes and hundreds of previously uncatalogued genomes.
- EvvyAI provides real-time microbiome guidance while escalating questions requiring expert judgment to clinicians.
- One mailed swab can produce clinician-reviewed results, interpretation, next steps and personalized prescriptions when relevant.
Risks & concerns
- Links between vaginal microbiomes and infertility, cancer, preterm birth, IVF success and recurrent pregnancy loss remain under investigation.
- High-quality, representative datasets measuring female biology remain insufficient for precision medicine and women’s health AI.
- Leading AI models still struggle with women’s health questions, limiting their usefulness without new biological data.
- Evvy’s long-term at-home Pap smear concept remains an ambition rather than an available product.
- Juno Bio, Tiny Health and Daye create competition in the developing vaginal health market.
